June 4, 2014—The 36-month results from the SYMPLICITY HTN-2 trial were published by Murray D. Esler, MD, et al, online ahead of print in European Heart Journal. Catheter-based renal denervation using the Symplicity renal denervation system (Medtronic, Inc.) resulted in sustained lowering of blood pressure at 3 years in a selected population of subjects with severe, treatment-resistant hypertension without serious safety concerns, concluded the investigators.
June 2, 2014—Cook Medical announced that the company is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava (IVC) filters.
May 29, 2014—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that a new meta-analysis found that renal artery stenting significantly reduces the risk of serious health problems, including death and stroke, when compared to medical therapy alone. The study, which was led by Alexandre Benjo, MD, was presented at the SCAI 2014 scientific sessions in Las Vegas, Nevada. Dr. Benjo is from the Ochsner Medical Center in New Orleans, Louisiana.
May 27, 2014—Spectranetics Corporation announced that it has entered into a definitive merger agreement to acquire AngioScore, Inc. for $230 million (50/50, cash and stock) plus further payments contingent on commercial and regulatory milestones. The transaction is subject to customary closing conditions. The company expects to close the acquisition on or near June 30, 2014. AngioScore will be a wholly owned subsidiary of Spectranetics.
May 22, 2014—St. Jude Medical, Inc. announced that preliminary results from the EnligHTN III study results were presented during a late-breaking clinical trial session at the EuroPCR 2014 congress being held May 20–23 in Paris, France. The study found that the company’s second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension 6 months postprocedure.
A study from Taiwan, published in EuroIntervention in May and presented at the EuroPCR congress (20–23 May 2014, Paris, France), shows that penile artery angioplasty is safe and can achieve clinically significant improvement in erectile function in 60% of patients with erectile dysfunction and isolated penile artery stenosis at six months.
Volcano Corporation has announced that it has signed an agreement to acquire AtheroMed, a privately-held company that has developed the Phoenix Atherectomy System used in the treatment of peripheral artery disease.
Ekos Corporation has announced that the US Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.
Surgery patients are much less likely to get a blood clot in the lower extremities or lungs if they receive preventive treatment based on their individual clotting risk, in addition to walking soon after the operation. Results from a surgical quality improvement study, appearing in the June issue of the Journal of the American College of Surgeons, indicate that the odds of this common and potentially life-threatening postoperative complication steadily declined after the implementation of a multicomponent prevention program in a hospital s department of surgery.
The tangled highway of blood vessels that twists and turns inside our bodies, delivering essential nutrients and disposing of hazardous waste to keep our organs working properly has been a conundrum for scientists trying to make artificial vessels from scratch. Now a team from Brigham and Women s Hospital (BWH) has made headway in fabricating blood vessels using a three-dimensional (3D) bioprinting technique.
In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment - which is to wait until the tumors have become resistant to hormone therapy before receiving chemotherapy.
Prostate cancer is one of the most common cancers in men and a major cause of cancer-related deaths. Yet it is tricky to diagnose - the commonly used PSA test can result in over- diagnosis and unnecessary further procedures. Now, new research led by the University of Adelaide in Australia promises to improve the accuracy of prostate cancer diagnosis with the help of biomarkers in seminal fluid.
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
The Advanta V12 stent (MAQUET) is the company’s proprietary balloon-expandable covered stent technology. Prof. Richard G McWilliams, Radiology Department, Royal Liverpool University Hospital, Liverpool, UK, spoke about his centre’s experience with the Advanta V12.
A study from Lublin, Poland, that set out to evaluate the results of selective catheterisation of occluded fallopian tubes and its effect on fertility was presented at the Global Embolization Symposium and Technologies US (GEST US, 1–4 May, San Francisco, USA) meeting.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos